拉米夫定联合阿德福韦酯对原发肝癌患者生活质量及机体改善效果研究被引量：1

Study on Lamivudine combined with Adefovir Dipivoxil for the quality of life and the body improving effect of patients with primary liver cancer

暂未订购

导出

摘要目的探讨拉米夫定与阿德福韦酯联合对原发肝癌患者的治疗效果，并分析治疗对患者生活质量和机体改善效果的影响。方法选择2012年2～12月北京市房山区第一医院收治的原发肝癌患者120例，随机分为联合组和对照组，每组各60例。对照组采用常规拉米夫定治疗，联合组加用阿德福韦酯联合治疗。比较两组肝肾功能、凝血功能、血清肌酐（SCr）、血常规等，并评价治疗24周后的客观疗效及生活质量和机体改善情况。结果治疗24周后，联合组总有效率为85．0％，明显高于对照组的61．7％，差异有统计学意义（P〈0．05）。联合组（好转＋稳定）率为98-3％，明显高于对照组的71．7％，差异有统计学意义（P〈0．05）。结论拉米夫定与阿德福韦酯联合治疗能有效提高患者的生存率，改善患者的生活质量及身体功能，值得临床推广应用。 Objective To explore the effect of Lamivudine and Adefovir Dipivoxil joint for the patients with primary liver cancer, and to analyze the treatment effect of the patient＇s quality of life and the body improving. Methods 120 cases of patients with primary liver cancer and liver from February to December 2012 in the First Hospital of Fangshan District in Beijing City were chosen and randomly divided into jointed group and control group with 60 cases in each group. The control group was used conventional Lamivudine treatment, jointed group was given the combination therapy with Adefovir Dipivoxil. The two groups of liver and kidney function, blood coagulation function, serum creatinine （SCr）, blood routine, etc. were compared, and treatment efficacy and quality of life and the body improving effect at 24 weeks were evaluated objectively. Results 24 weeks after treatment, the efficacy rate of jointed group was 85.0%, which was higher than that in the control group of 61.7%, the difference was statistically significant （P 〈 0.05）. The improved and stability rate was 98.3%, which was higher than that in the control group of 71.7%, the difference was statistically significant （P 〈 0.05）. Conclusion Lamivudine and Adefovir Dipivoxil combination therapy can effectively improve the patient＇s survival rate, improve patient＇s quality of life and the body function, which is worthy of clinical popularization and application.

作者黄荣华

机构地区北京市房山区第一医院药剂科

出处《中国医药导报》 CAS 2013年第31期93-96,共4页 China Medical Herald

关键词拉米夫定阿德福韦酯原发肝癌生活质量机体改善效果 Lamivudine Adefovir Dipivoxil Primary liver cancer Quality of life Body improvements

分类号 R735.7 [医药卫生—肿瘤]

引文网络
相关文献

参考文献21

1Mahmood S,Niiyama G,Kamei A,et al. Influence of viral loadand genotype in the progression of Hepatitis B - associated liv-er cirrhosis to hepatocellular carcinoma [J]. Liver Int,2005,25 :220-225.
2Wands JR. Prevention of hepatocellular carcinoma [J]. N EnglJ Med,2004,351;1567-1570.
3张雪峰,王斌,钱冬萌,吴宝叶,石海英,刘淑清,闫安,高红梅,闫丽娟,康燕,李宝华.循环DNA和HBV-DNA载量与原发性肝癌的相关性探讨[J].现代生物医学进展,2011,11(19):3713-3715. 被引量：4
4Hann HW,Fontana RJ,Wright T,et al. A United States com-passionate use study of lamivudine treatment in nontransplan-tation candidateswith decompensated hepatitis B virus2relatedcirrhosis [J]. Liver Transpl, 2003,9 : 49-56.
5Beasley RP. Hepatitis B virus : the major etiology of hepato-cellular carcinoma [J]. Cancer, 1988,61 (10) : 1942.
6Benedict G, Norris PS,Ware CF. To kill or be killed : viralevasion of apoptosis [J]. Nat Immunol,2002,3 : 1013.
7曹红卫,卫国,冯文曦,龚小云,郑江.乙肝病毒DNA荧光定量PCR检测及其意义[J].第三军医大学学报,2001,23(7):866-868. 被引量：34
8Bolukbas C, Bolukbas FF, Kendir T,et al. The effectivenessof lamivudine treatment in cirrhotic patients with HBV pre-coremutations :a prospective,open-labelstudy [J]. Dig Dis Sci,2006,51:1196-1202.
9Shaw T, Locamini S. Entecavir for the treatment of chronichepatitis B [J]. Expert Rev Anti Infect Ther, 2004,2 : 853-871.
10Nagamatsu H, Itano S, Nagaoka S,et al. ProlhylacticLamiva-dine administration prevents exacerbation of liver damageinHBeantigen positive patients with hepatocellular carcinomaundergoing transhepatic arterial infusion chemotherapy [J],Am J Gastroenterol, 2004,99 (12) :2369.

二级参考文献33

1姚集鲁主编.传染病学临床专沦[M].广州:广东高等教育出版社.2000:18.
2Chun YK, Kim JY, Woo H J, et al. No significant correlation exists between core promoter mutations, viral replication, and liver damage in chronic hepatitis B infection [ J ]. Hepatology, 2000, 32 ( 5 ) : 1154-1162.
3Lindh M, Horal P, Dhillon AP, et al. Hepatitis B virus DNA levels, precore mutations, genotypes and histological activity in chronic hepatitis B [J]. J Viral Hepatol, 2000, 7(4) : 258-267.
4Liaw YF. Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy [ J ]. Antivir Ther, 2006, 11 (6) : 669 -679.
5Fan HM, Zhang CL, Ying RS, et al. Relationship between liver pathological characteristics and serum l-IBeAg and HBV-DNA in 1057 patients with chronic hepatitis B [ J ]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi, 2008, 22(2) : 130-132.
6Fung J, Lai CL, But D, et al. Prevalence of fibrosis and cirrhosis in chronic hepatitis B: implications for treatment and management [ J]. Am J Gastroenterol, 2008, 103(6) : 1421-142.
7Ke WM, Xie SB, Yu LN, et al. Delince of serum HBV-DNA and no change apportioned by the same hepatic parenchyma cell volume from hepatitic fibrosis stage 1 to stage 4 during the natural history of chronic hepatitis B [J]. Intervirology, 2008, 51 (4): 235-240.
8Benedict C, Norris PS, Ware CF. To kill or be killed: viral evasionof apoptosis[J]. Nat Immunol2002;3:1013-1013.
9Pasquetto V, Wieland S, Chisari FV. Intracellular hepatitis B virusnucleocapsids survive cytotoxic T-lymphocyte-induced apoptosis [J]. J Virol 2000;74:9792-9796.
10Shapiro B, Chakrabarty M, Cohn E M, et al. Determination of cimulating DNA levels in patients with benign or malignant gastrointestinal disease[J].Cancer(Phila), 1983, 51:2116-2120.